Discriminative stimulus effects of hallucinogenic drugs: A possible relation to reinforcing and aversive effects

Journal of Pharmacological Sciences

Volumn 120, Issue 2, 2012, Pages 70-76

  Mori, Tomohisa ^a   Yoshizawa, Kazumi ^a   Shibasaki, Masahiro ^a   Suzuki, Tsutomu ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Discriminative stimulus effect; Hallucinogen; Serotonin; Sigma 1 ( 1) receptor

Indexed keywords

EID: 84868033107     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12R08CP     Document Type: Review

References (37)

1. Fiorella D, Rabin RA, Winter JC. Role of 5-HT2A and 5-HT2Creceptors in the stimulus effects of hallucinogenic drugs. II: Reassessmentof LSD false positives. Psychopharmacology (Berl).1995;121:357-363.
2. Nielsen EB. Discriminative stimulus properties of lysergic aciddiethylamide in the monkey. J Pharmacol Exp Ther. 1985;234:244-249.
3. Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, CumbayMG, Lisnicchia JG, Nichols DE. Re-evaluation of lisuride pharmacology:5-hydroxytryptamine1A receptor-mediated behavioraleffects overlap its other properties in rats. Psychopharmacology(Berl). 2002;164:93-107.
4. Cole JC, Sumnall HR. The pre-clinical behavioural pharmacologyof 3,4-methylenedioxymethamphetamine (MDMA). NeurosciBiobehav Rev. 2003;27:199-217.
5. Goodwin AK, Pynnonen DM, Baker LE. Serotonergic-dopaminergicmediation of MDMA's discriminative stimulus effects in athree-choice discrimination. Pharmacol Biochem Behav. 2003;74:987-995.
6. Glennon RA, Young R. MDMA stimulus generalization to the5-HT(1A) serotonin agonist 8-hydroxy-2-(di-n-propylamino)tetralin. Pharmacol Biochem Behav. 2000;66:483-488.
7. Winter JC. Hallucinogens as discriminative stimuli in animals:LSD, phenethylamines, and tryptamines. Psychopharmacology(Berl). 2009;203:251-263.
8. Orejarena MJ, Lanfumey L, Maldonado R, Robledo P. Involvementof 5-HT2A receptors in MDMA reinforcement and cueinducedreinstatement of MDMA-seeking behaviour. Int J Neuropsychopharmacol.2011;14:927-940.
9. Mori T, Ito S, Kuwaki T, Yanagisawa M, Sakurai T, Sawaguchi T.Monoaminergic neuronal changes in orexin deficient mice. Neuropharmacology. 2010;58:826-832.
10. Willetts J, Balster RL. Pentobarbital-like discriminative stimuluseffects of N-methyl-D-aspartate antagonists. J Pharmacol ExpTher. 1989;249:438-443.
11. Mori T, Nomura M, Yoshizawa K, Nagase H, Sawaguchi T, NaritaM, et al. Generalizaiton of NMDA-receptor agonists U-50,488H,but not TRK-820 in rats. J Pharmacol Sci. 2006;100:157-161.
12. Mori T, Baba J, Ichimaru Y, Suzuki T. Effects of rolipram, a selectiveinhibitor of phosphodiesterase 4, on hyperlocomotion inducedby several abused drugs in mice. Jpn J Pharmacol. 2000;83:113-118.
13. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Autoradiographicdifferentiation of mu, delta, and kappa opioid receptorsin the rat forebrain and midbrain. J Neurosci. 1987;7:2445-2464.
14. Baker LE, Panos JJ, Killinger BA, Peet MM, Bell LM, HaliwLA, et al. Comparison of the discriminative stimulus effects ofsalvinorin A and its derivatives to U69,593 and U50,488 in rats.Psychopharmacology (Berl). 2009;203:203-211.
15. Yoshizawa K, Narita M, Saeki M, Narita M, Isotani K, HoriuchiH, et al. Activation of extracellular signal-regulated kinase iscritical for the discriminative stimulus effects induced by U-50,488H. Synapse. 2011;65:1052-1061.
16. Mori T, Yoshizawa K, Nomura M, Isotani K, Torigoe K,Tsukiyama Y, et al. Sigma-1 receptor function is critical for boththe discriminative stimulus and aversive effects of the kappaopioidreceptor agonist U-50488H. Addict Biol. 2012;17:717-724.
17. Narita M, Yoshizawa K, Aoki K, Takagi M, Miyatake M, SuzukiT. A putative sigma1 receptor antagonist NE-100 attenuates thediscriminative stimulus effects of ketamine in rats. Addict Biol.2001;6:373-376.
18. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER- mitochondrioninterface regulate Ca(2+) signaling and cell survival.Cell. 2007;131:596-610.
19. Bruchas MR, Xu M, Chavkin C. Repeated swim stress induceskappa opioid-mediated activation of extracellular signal-regulatedkinase 1/2. Neuroreport. 2008;19:1417-1422.
20. Kyosseva SV, Owens SM, Elbein AD, Karson CN. Differentialand region-specific activation of mitogen-activated protein kinasesfollowing chronic administration of phencyclidine in ratbrain. Neuropsychopharmacology. 2001;24:267-277.
21. Cormaci G, Mori T, Hayashi T, Su TP. Protein kinase A activationdown-regulates, whereas extracellular signal-regulated kinaseactivation up-regulates sigma-1 receptors in B-104 cells: implicationfor neuroplasticity. J Pharmacol Exp Ther. 2007;320:202-210.
22. Su TP, Hayashi T, Vaupel DB. When the endogenous hallucinogenictrance amine N,N-dimethyltryptamine meets the sigma-1receptor. Sci Signal. 2009;2:pe12.
23. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M,Watanabe M. Endocannabinoid-mediated control of synaptictransmission. Physiol Rev. 2009;89:309-380.
24. Carvalho AF, Van Bockstaele EJ. Direct intra-accumbal infusionof a beta-adrenergic receptor antagonist abolishes WIN55,212-2-induced aversion. Neurosci Lett. 2011;500:82-85.
25. Cichewicz DL. Synergistic interactions between cannabinoid andopioid analgesics. Life Sci. 2004;74:1317-1324.
26. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, Matsubara T,et al. mu-Opioid receptor forms a functional heterodimer withcannabinoid CB1 receptor: electrophysiological and FRET assayanalysis. J Pharmacol Sci. 2008;108:308-319.
27. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL,Maldonado R. Motivational effects of cannabinoids are mediatedby mu-opioid and kappa-opioid receptors. J Neurosci. 2002;22:1146-1154.
28. Solinas M, Zangen A, Thiriet N, Goldberg SR. β-Endorphin elevations in the ventral tegmental area regulate the discriminativeeffects of δ9-tetrahydrocannabinol. Eur J Neurosci. 2004;19:3183-3192.
29. Li JX, McMahon LR, Gerak LR, Becker GL, France CP. Interactionsbetween Delta(9)-tetrahydrocannabinol and mu opioid receptoragonists in rhesus monkeys: discrimination and antinociception.Psychopharmacology (Berl). 2008;199:199-208.
30. Mori T, Shibasaki M, Abe M, Udagawa Y, Suzuki T. Effects ofdronabinol on morphine-induced dopamine-related behavioraleffects in animals. Synapse. 2012;66:931-937.
31. Rios C, Gomes I, Devi LA. Mu opioid and CB1 cannabinoid receptorinteractions: reciprocal inhibition of receptor signalingand neuritogenesis. Br J Pharmacol. 2006;148:387-395.
32. Suzuki T, Mori T, Tsuji M, Misawa M, Nagase H. Discriminativestimulus properties of morphine mediated by mu1-opioid receptors.Eur J Pharmacol. 1995;284:195-198.
33. D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, PittmanB, et al. Effects of haloperidol on the behavioral, subjective,cognitive, motor, and neuroendocrine effects of delta-9-tetrahydrocannabinolin humans. Psychopharmacology (Berl). 2008;198:587-603.
34. Bronson ME, Lin YP, Burchett K, Picker MJ, Dykstra LA. Serotonininvolvement in the discriminative stimulus effects of kappaopioids in pigeons. Psychopharmacology (Berl). 1993;111:69-77.
35. Di Benedetto M, Bastias Candia Sdel C, D'Addario C, PorticellaEE, Cavina C, Candeletti S, et al. Regulation of opioid gene expressionin the rat brainstem by 3,4-methylenedioxymethamphetamine(MDMA): role of serotonin and involvement of CREBand ERK cascade. Naunyn Schmiedebergs Arch Pharmacol.2011;383:169-178.
36. Dumont GJ, van Hasselt JG, de Kam M, van Gerven JM, TouwDJ, Buitelaar JK, et al. Acute psychomotor, memory and subjectiveeffects of MDMA and THC co-administration over time inhealthy volunteers. J Psychopharmacol. 2011;25:478-489.
37. Barrett RL, Wiley JL, Balster RL, Martin BR. Pharmacologicalspecificity of delta 9-tetrahydrocannabinol discrimination in rats.Psychopharmacology (Berl). 1995;118:419-424.